Key Takeaways
- Shares of HIMS are climbing 7% in Thursday’s premarket session, building on Wednesday’s 10% rally for a fourth consecutive session of advances
- Week-to-date performance shows a staggering 64% increase — marking the company’s strongest weekly showing in its trading history
- Catalyst for the explosive move: a strategic partnership with Novo Nordisk enabling HIMS to distribute FDA-cleared Ozempic and Wegovy through its platform
- Wall Street responds: Barclays lifts price target to $29 from $25 maintaining “overweight”; BofA upgrades to “neutral” from “underperform” with $23 target
- Fourth quarter results delivered impressive earnings surprise: $0.08 per share versus $0.02 consensus, while revenue of $617.8M fell just short of $619.5M expectations
Hims & Hers Health (HIMS) is experiencing a breakout week that’s rewriting its record books. Shares advanced approximately 7% in Thursday morning’s premarket session, extending Wednesday’s robust 10% climb. This marks the fourth trading day in a row of positive momentum.
Hims & Hers Health, Inc., HIMS
As of Wednesday’s closing bell, the stock has rocketed 64% higher this week. It represents the strongest weekly gain in the company’s entire public trading history.
The extraordinary run began Monday following the announcement that Novo Nordisk will make its blockbuster weight-loss medications available through the Hims & Hers digital ecosystem. This arrangement effectively removes a significant legal uncertainty that had weighed on investor sentiment.
The partnership enables Hims & Hers to offer FDA-authorized Ozempic and Wegovy directly to consumers via its telehealth platform. Market analysts view this development as a meaningful catalyst for both top-line growth and profit margins.
Midday Wednesday saw HIMS trading at $26.17, representing a $2.70 single-day gain, while trading volume reached 51.6 million shares — significantly exceeding the typical 33.3 million average.
Wall Street Raises Price Targets
The Novo Nordisk collaboration prompted several investment firms to revise their outlooks. Barclays increased its price objective from $25 to $29 while reaffirming an “overweight” stance. This target suggests approximately 10.8% additional upside potential.
Bank of America shifted its rating from “underperform” to “neutral” and dramatically raised its price target from $12.50 to $23. Deutsche Bank also adjusted higher, moving from $25 to $28 while keeping a “hold” recommendation.
According to MarketBeat data, the analyst consensus stands at “Hold” with an average price target of $30.75. The breakdown shows three Buy ratings, thirteen Hold ratings, and one Sell recommendation.
Options traders showed significant interest, with approximately 322,000 call contracts changing hands — indicating strong bullish sentiment that can potentially accelerate upward price movement.
Fourth Quarter Performance and Capital Return
The company unveiled its Q4 financial results on February 23. Earnings per share registered at $0.08, substantially exceeding the Street’s $0.02 forecast. Top-line revenue reached $617.8 million, narrowly missing the $619.5 million analyst consensus.
Despite the minor revenue shortfall, sales grew 28.4% compared to the prior-year period. The company achieved a return on equity of 22.48% alongside a net margin of 5.47%.
Management also authorized a $250 million share repurchase program, representing approximately 3% of shares outstanding. Such capital allocation decisions often indicate executive confidence that current valuations are attractive.
For the full fiscal year ahead, Wall Street projects earnings per share of $0.29.
The stock’s 52-week trading range spans from $13.74 to $70.43. Wednesday’s close positioned shares well above the 50-day moving average of $24.31, though still trailing the 200-day moving average of $37.75.
Notwithstanding this week’s impressive performance, elevated short interest remains a factor to monitor. Some analysts have noted that squeeze dynamics could be contributing to volatility — momentum driven by short covering can potentially reverse once speculative interest subsides.
Institutional investors control 63.52% of outstanding HIMS shares. Company insiders own 17.71%, though insider selling totaled 80,463 shares during the most recent quarter.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
